Due to the possible positive effects on disorders characterized by lipid deposition and inflammation such as NAFL or NASH, several molecules, either agonist or antagonist of the various PPAR subtypes, have been developed and initially tested in in vitro or in vivo models. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.